Radiopharm (RADX) announced that it has received a recommendation from the Data Safety and Monitoring Committee, or DSMC, to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the next dose level of 130mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2-positive advanced solid tumors. The DSMC is a multidisciplinary committee that conducts detailed reviews of study data, discusses potential safety events and provides recommendations regarding trial continuation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
- Radiopharm Theranostics Taps Siemens for U.S. Supply of Fast-Tracked Brain Metastases Imaging Agent RAD101
- Biotech Alert: Searches spiking for these stocks today
- Radiopharm Theranostics Doses First Patient in Phase 1 RAD 402 Prostate Cancer Trial
- Buy Rating on RADX Driven by Promising RAD 101 Phase 2b Imaging Data and Clear 2026 Clinical Milestones
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Trial of 177Lu-BetaBart